Therapeutic use of flunarizine in the treatment arteriopathies of the lower extremities
Abstract
94 patients with Stage II obliterating arteriopathy of the lower extremities, treated with Flunarizine (10-20 mg per diem), were checked every two months for a 6 month period. Of the 76 patients reaching the final check up, 58 had received no previous treatment and 18 had ischemias secondary to reconstructive vascular surgery. Clinical improvement in terms of increased independent mobility and improved Doppler flowmeter pressure readings were noted in both groups. In view of its beneficial effects on blood vessel function in other areas, Flunarizine is felt to be a valuable drug for the treatment of peripheral arteriopathies, both initially and in cases of ischaemia following vascular surgery.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 94 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.